All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
On September 30, 2022, KITE-222, an investigational chimeric antigen receptor (CAR) T-cell therapy, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia (AML).1
This autologous CAR T-cell therapy targets C-type lectin-like molecule-1 (CLL-1). While CLL-1 is expressed in lineage-committed myeloid cells in up to 90% of patients with AML, it is not expressed in healthy hematopoietic stem cells.1
A phase I open-label, multicenter trial evaluating the safety of KITE-222 in patients with relapsed/refractory AML is currently enrolling (NCT04789408).
Progress in immunotherapy for hematologic malignancies
Immunotherapy has long been part of the armamentarium of therapies for hematologic malignancies. One of the first applications of immunotherapy was the use of allogeneic stem cell transplantation...
CD33/CLL1 compound CAR T cells in relapsed/refractory AML
During the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress, Fang Liu1 presented the interim results of a phase I trial (NCT03795779) in which CD33/CLL1...
Subscribe to get the best content related to AML delivered to your inbox